|
From Dan Ollendorf, PhD, MPH, ICER’s Chief Scientific Officer and Director of HTA Methods and Engagement:
Now that ISPOR 2026 is in the books, it’s a great time to reflect on the experience and key learnings. But first and foremost, I want to share my great pride about the breadth and depth of research presented by the ICER team, which covered a wide range of topics from enhancing economic models with patient input and AI, to better understanding clinical and economic evidence, to balancing innovation and affordability.
It was also particularly gratifying to hear a plenary speaker commend ICER as a health technology assessment (HTA) leader for the US. That’s what 20 years of hard and thoughtful work will do!
The broader conference provided many important themes to digest and consider. Three topics stood out to me:
-
The continued importance of health economics outcomes research (HEOR): Presenters consistently highlighted the advantages of clearly outlining the value propositions for new innovations using HEOR – this is especially important for transformational or potentially curative treatments that can make a real difference for patients.
-
AI was ever-present: With presentations on AI-enabled literature synthesis, RWE analyses, and economic modeling, there was much discussion on how AI could be utilized in the HEOR space. Unlike prior years, however, there were also important conversations about the appropriate level of governance, risk mitigation, and human interaction needed to make AI a reality.
-
An emphasis on global pricing strategies: And last but certainly not least, there were conversations about the shift of pricing policy from a jurisdiction-specific conversation to a global one, with the impact of US trade policy at the forefront. Implications for product launch strategy, pressure on foreign governments to raise prices, potential shifts in the location and level of investment in biopharmaceutical development – you name it, it was discussed.
Many questions remain, but I left the conference feeling hopeful. ICER’s commitment — along with that of many others — to evidence-based analysis, transparency, and ethics will remain central to HEOR discussions.
|